Chao‐Chi Ho

5.7k total citations
133 papers, 3.8k citations indexed

About

Chao‐Chi Ho is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Chao‐Chi Ho has authored 133 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 85 papers in Pulmonary and Respiratory Medicine, 49 papers in Oncology and 31 papers in Molecular Biology. Recurrent topics in Chao‐Chi Ho's work include Lung Cancer Treatments and Mutations (55 papers), Lung Cancer Diagnosis and Treatment (35 papers) and Lung Cancer Research Studies (22 papers). Chao‐Chi Ho is often cited by papers focused on Lung Cancer Treatments and Mutations (55 papers), Lung Cancer Diagnosis and Treatment (35 papers) and Lung Cancer Research Studies (22 papers). Chao‐Chi Ho collaborates with scholars based in Taiwan, United States and Spain. Chao‐Chi Ho's co-authors include Chong‐Jen Yu, Pan‐Chyr Yang, Jin‐Yuan Shih, James Chih‐Hsin Yang, Wei‐Yu Liao, Huei‐Wen Chen, Hsin‐Yi Huang, Pei‐Hsin Huang, Kuan‐Yu Chen and Sung‐Liang Yu and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Nano Letters.

In The Last Decade

Chao‐Chi Ho

127 papers receiving 3.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chao‐Chi Ho Taiwan	33	1.7k	1.4k	1.3k	651	463	133	3.8k
Xianglin Yuan China	36	1.1k 0.6×	1.2k 0.9×	2.3k 1.8×	1.0k 1.6×	633 1.4×	233	5.0k
Konstantinos N. Syrigos Greece	42	1.7k 1.0×	2.7k 1.9×	2.0k 1.5×	754 1.2×	838 1.8×	198	5.7k
Carlos Gil Ferreira Brazil	35	1.4k 0.8×	1.7k 1.2×	1.6k 1.2×	565 0.9×	282 0.6×	179	4.2k
Lei Li China	35	599 0.3×	1.5k 1.1×	1.7k 1.3×	764 1.2×	530 1.1×	147	3.8k
Yang Xia China	38	849 0.5×	841 0.6×	2.1k 1.6×	952 1.5×	707 1.5×	195	4.5k
Tangfeng Lv China	37	1.5k 0.9×	1.7k 1.2×	2.7k 2.1×	1.3k 2.1×	736 1.6×	219	5.1k
Kaixiong Tao China	39	993 0.6×	1.3k 0.9×	2.4k 1.9×	1.0k 1.6×	644 1.4×	285	5.2k
Lin Li China	34	2.7k 1.6×	2.3k 1.7×	2.1k 1.6×	1.1k 1.7×	353 0.8×	210	5.9k
Yan Li China	31	1.0k 0.6×	1.5k 1.1×	1.5k 1.1×	770 1.2×	520 1.1×	207	4.4k
Rita Mancini Italy	36	627 0.4×	956 0.7×	2.1k 1.6×	950 1.5×	429 0.9×	199	4.3k

Countries citing papers authored by Chao‐Chi Ho

Since Specialization

Citations

This map shows the geographic impact of Chao‐Chi Ho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chao‐Chi Ho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chao‐Chi Ho more than expected).

Fields of papers citing papers by Chao‐Chi Ho

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chao‐Chi Ho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chao‐Chi Ho. The network helps show where Chao‐Chi Ho may publish in the future.

Co-authorship network of co-authors of Chao‐Chi Ho

This figure shows the co-authorship network connecting the top 25 collaborators of Chao‐Chi Ho. A scholar is included among the top collaborators of Chao‐Chi Ho based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chao‐Chi Ho. Chao‐Chi Ho is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liao, Wei‐Yu, Chao‐Chi Ho, Shang‐Gin Wu, et al.. (2025). Enhanced detection of actionable mutations in NSCLC through pleural effusion cell-free DNA sequencing: A prospective study. European Journal of Cancer. 217. 115224–115224. 1 indexed citations

Lin, Chun‐Chieh, et al.. (2025). Prognostic factors in cavitary non-tuberculous mycobacterial pulmonary disease and proposal of Double-7 imaging pattern: A multicenter cohort study. Journal of Microbiology Immunology and Infection. 58(5). 593–599. 1 indexed citations

Hsiao, Fei‐Hsiu, et al.. (2025). The Mindful Compassion Program Integrated with Body-Mind-Spirit Empowerment for Reducing Depression in Lung Cancer Patient-Caregiver Dyads. Psychosocial Intervention. 34(1). 1–9.

Hsiung, Chia‐Ni, et al.. (2025). Lipid Levels and Lung Cancer Risk: Findings from the Taiwan National Data Systems from 2012 to 2018. Journal of Epidemiology and Global Health. 15(1). 11–11.

Liao, Wei‐Yu, Chao‐Chi Ho, Jin‐Yuan Shih, et al.. (2024). Real-world analysis of survival outcomes in advanced EGFR-mutant NSCLC patients treated with platinum-pemetrexed after EGFR-TKI treatment failure. Journal of the Formosan Medical Association. 124(8). 759–766. 1 indexed citations

Lee, T D, Fengchao Yu, Cheng‐An J. Lin, et al.. (2024). Mapping Nanoscale‐To‐Single‐Cell Phosphoproteomic Landscape by Chip‐DIA. Advanced Science. 12(1). e2402421–e2402421. 4 indexed citations

Tseng, Jeng‐Sen, Kun‐Chieh Chen, Mong‐Wei Lin, et al.. (2024). Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR-mutant lung adenocarcinoma treated with first-line osimertinib. Therapeutic Advances in Medical Oncology. 16. 2665342–2665342. 1 indexed citations

Wu, Shang‐Gin, Chao‐Chi Ho, James Chih‐Hsin Yang, et al.. (2024). Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis. Clinical and Translational Medicine. 15(1). e70149–e70149. 4 indexed citations

Liang, Sheng‐Kai, Li‐Ta Keng, Meng‐Rui Lee, et al.. (2023). Oral uracil–tegafur compared with intravenous chemotherapy as adjuvant therapy for resected early‐stage non‐small cell lung cancer patients. Cancer Medicine. 12(17). 17993–18004. 3 indexed citations

10.

Yang, Ching‐Yao, Jin‐Yuan Shih, Wei‐Yu Liao, et al.. (2023). Upfront liquid next-generation sequencing in treatment-naïve advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health system. European Journal of Cancer. 193. 113310–113310. 5 indexed citations

11.

Lin, Yen‐Ting, Chao‐Chi Ho, Wei‐Hsun Hsu, et al.. (2023). Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first‐line EGFR inhibitor resistance in lung cancer. Cancer Medicine. 13(1). e6870–e6870. 4 indexed citations

12.

Wu, Ming‐Fang, et al.. (2023). Regulation of dendritic cell maturation in osimertinib-treated lung adenocarcinoma patients. Journal of the Formosan Medical Association. 122(9). 955–960. 2 indexed citations

13.

Ko, Chun‐Jung, Ching‐Tai Lee, Cheng‐Fan Lee, et al.. (2021). Afatinib Exerts Immunomodulatory Effects by Targeting the Pyrimidine Biosynthesis Enzyme CAD. Cancer Research. 81(12). 3270–3282. 22 indexed citations

14.

Lin, Ching‐Kai, et al.. (2021). Cone-Beam Computed Tomography-Derived Augmented Fluoroscopy Improves the Diagnostic Yield of Endobronchial Ultrasound-Guided Transbronchial Biopsy for Peripheral Pulmonary Lesions. Diagnostics. 12(1). 41–41. 12 indexed citations

15.

Su, Sheng‐Fang, Chia-Hsin Liu, Chao‐Chi Ho, et al.. (2021). Genome-Wide Epigenetic Landscape of Lung Adenocarcinoma Links HOXB9 DNA Methylation to Intrinsic EGFR-TKI Resistance and Heterogeneous Responses. JCO Precision Oncology. 5(5). 418–431. 14 indexed citations

16.

Lin, Chien‐Chin, et al.. (2020). Mucosa‐associated lymphoid tissue lymphoma with isolated endobronchial involvement. Respirology Case Reports. 8(8). e00672–e00672. 3 indexed citations

17.

Ho, Chao‐Chi, et al.. (2020). Plasma-activated medium as adjuvant therapy for lung cancer with malignant pleural effusion. Scientific Reports. 10(1). 18154–18154. 12 indexed citations

18.

Yeh, Chi‐Tai, Alexander T.H. Wu, Peter Mu‐Hsin Chang, et al.. (2012). Trifluoperazine, an Antipsychotic Agent, Inhibits Cancer Stem Cell Growth and Overcomes Drug Resistance of Lung Cancer. American Journal of Respiratory and Critical Care Medicine. 186(11). 1180–1188. 170 indexed citations

19.

Hsieh, Wan-Yu, Cheng‐Chung Chou, Chao‐Chi Ho, et al.. (2011). Single-Walled Carbon Nanotubes Induce Airway Hyperreactivity and Parenchymal Injury in Mice. American Journal of Respiratory Cell and Molecular Biology. 46(2). 257–267. 28 indexed citations

20.

Ho, Chao‐Chi, Wei‐Yu Liao, Yung‐Ming Chen, et al.. (2007). TREM-1 Expression in Tumor-associated Macrophages and Clinical Outcome in Lung Cancer. American Journal of Respiratory and Critical Care Medicine. 177(7). 763–770. 122 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact